(IN BRIEF) Eckert & Ziegler Radiopharma GmbH has entered into a clinical manufacturing agreement with Pentixapharm AG to supply GMP-grade Y90-PentixaTher doses for use in ongoing trials. The radiolabeled therapy targets cancers overexpressing the CXCR4 receptor and supports a theranostic … Read the full press release →
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Acute myeloid leukemia, cancer treatment, clinical trials, CXCR4, Dirk Pleimes, Eckert & Ziegler, EZR, Ga68-PentixaFor, GMP manufacturing, Harald Hasselmann, lymphoma, Myeloma, nuclear medicine, Pentixapharm, radiopharmaceuticals, radiotherapy, solid tumors, targeted therapy, theranostics, Y90-PentixaTher